Targeting lymphatic vessel activation and CCL21 production by vascular endothelial growth factor receptor-3 inhibition has novel immunomodulatory and antiarteriosclerotic effects in cardiac allografts. (Q50559921)
Jump to navigation
Jump to search
scientific article published on 15 March 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Targeting lymphatic vessel activation and CCL21 production by vascular endothelial growth factor receptor-3 inhibition has novel immunomodulatory and antiarteriosclerotic effects in cardiac allografts. |
scientific article published on 15 March 2010 |
Statements
Targeting lymphatic vessel activation and CCL21 production by vascular endothelial growth factor receptor-3 inhibition has novel immunomodulatory and antiarteriosclerotic effects in cardiac allografts (English)
Mikko A I Keränen
Antti I Nykänen
Henrik Sandelin
Raimo Tuuminen
Terhi Kärpänen
Yan Wu
Petri K Koskinen
15 March 2010